Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.67 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564884 | 0.85 | PDE5A (0.71) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL5565167 | 0.84 | PDE5A (0.72) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL5560131 | 0.83 | PDE5A (0.71) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL5566165 | 0.83 | PDE5A (0.74) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL3071620 | 0.83 | PDE5A (0.71) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL5565062 | 0.83 | PDE5A (0.77) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL5565319 | 0.80 | PDE5A (0.67) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL3076641 | 0.80 | PDE5A (0.67) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL187837 | 0.80 | PDE5A (1.00) | PDE5AHIF1AEPAS1KDM4ENPC1 | |
| SCHEMBL29352550 | 0.80 | PDE5A (1.00) | PDE5AHIF1AEPAS1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0932403-B1 | CONDENSED (HETARYL-SUBSTITUTED) 1-BENZYL-3-PYRAZOL DERIVATES FOR TREATING DISEASES OF THE CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEMS | BAYER HEALTHCARE AG (DE) | 2005-11-30 | — | — | EP | claimed |
| US-20050187276-A1 | Compounds, compositions and methods | BIZBIOTECH CO., LTD. (KR) | 2005-08-25 | — | — | US | claimed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | claimed |
| US-6180656-B1 | CARDIOVASCULAR DISORDERS; NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-30 | — | — | US | claimed |
| CN-1240354-A | Use of condensated (hetaryl-substituted) 1-benzal-3-pyarzol derivates for treating special diseases of the cardiovascular and the central nerous systems | BAYER AG (DE) | 2000-01-05 | — | — | CN | claimed |
| EP-0932403-A1 | USE OF CONDENSATED (HETARYL-SUBSTITUTED) 1-BENZAL-3-PYRAZOL DERIVATES FOR TREATING SPECIAL DISEASES OF THE CARDIOVASCULAR AND THE CENTRAL NERVOUS SYSTEMS | BAYER AG (DE) | 1999-08-04 | — | — | EP | claimed |
| WO-1998016223-A1 | USE OF CONDENSATED (HETARYL-SUBSTITUTED) 1-BENZAL-3-PYRAZOL DERIVATES FOR TREATING SPECIAL DISEASES OF THE CARDIOVASCULAR AND THE CENTRAL NERVOUS SYSTEMS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-04-23 | — | — | WO | claimed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-7226941-B2 | Compound for treating angiogenesis | HIF BIO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20050187276-A1 | Compounds, compositions and methods | BIZBIOTECH CO., LTD. (KR) | 2005-08-25 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | PDE5A 255/4885HIF1A 2016/4885EPAS1 1859/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | PDE5A 250/4885HIF1A 2281/4885EPAS1 1947/4885 |
| US-20050187276-A1 | Compounds, compositions and methods | HIF1A, HIF1AN, EGLN3 | PDE5A 1987/4885HIF1A 1/4885EPAS1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.